共 50 条
- [21] Impact of Fremanezumab on Disability in Migraine Patients With Medication Overuse and Documented Inadequate Response to 2-4 Classes of Preventive Treatments: Subgroup Analysis of the FOCUS StudyHEADACHE, 2020, 60 : 17 - 18Ashina, M.Cohen, J. M.Ramirez-Campos, VJanka, L.
- [22] Efficacy and safety of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS studyJOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):Ferrari, Michel D.Diener, Hans ChristophNing, XiaopingGalic, MajaCohen, Joshua M.Yang, RonghuaAshina, Messoud
- [23] Early onset of response to fremanezumab in migraine patients with moderate to severe depression and documented inadequate response to 2-4 classes of migraine preventive treatments: subgroup analysis of the randomised, placebo-controlled FOCUS studyCEPHALALGIA, 2019, 39 : 209 - 210Blumenfeld, AndrewYang, RonghuaCohen, Joshua M.Ramirez-Campos, VerenaRosich, Patricia Pozo
- [24] Impact of fremanezumab on headache-related disability in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS studyCEPHALALGIA, 2019, 39 : 224 - 225Ashina, MessoudFerrari, Michel D.Ning, XiaopingGalic, MajaCohen, Joshua M.Yang, Ronghua
- [25] Reduction in the number of headache hours and days with fremanezumab in patients with migraine and documented inadequate response to 2-4 migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS studyEUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 798 - 798Karppa, M.Ning, X.Galic, M.Cohen, J. M.Yang, R.
- [26] Impact of fremanezumab on migraine-associated symptoms in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS studyCEPHALALGIA, 2019, 39 : 223 - 223McAllister, PeterNing, XiaopingGalic, MajaCohen, Joshua M.Yang, Ronghua
- [27] Work productivity and activity impairment in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study of fremanezumabEUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 799 - 800Lipton, R. B.Pozo Rosich, P.Ning, X.Galic, M.Cohen, J. M.Yang, R.
- [28] Efficacy With Fremanezumab in Migraine Patients With Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS StudyNEUROLOGY, 2020, 94 (15)Buse, DawnCohen, JoshuaRamirez-Campos, VerenaYang, RonghuaNing, XiaopingGalic, MajaLipton, Richard B.
- [29] Efficacy with Fremanezumab in Migraine Patients with Comorbid Moderate to Severe Depression and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Placebo-Controlled FOCUS StudyANNALS OF NEUROLOGY, 2020, 88 : S159 - S160Lipton, Richard B.Cohen, Joshua M.Campos, Verena RamirezYang, RonghuaNing, XiaopingGalic, MajaBuse, Dawn C.
- [30] Clinically Meaningful Responses to Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Multicenter, Randomized, Placebo-controlled FOCUS StudyHEADACHE, 2019, 59 : 23 - 24Spierings, E.Ning, X.Galic, M.Cohen, J. M.Yang, R.